Could President Trump Reschedule Cannabis to Schedule III by Executive Order in the Coming Days?

Over the last several days, multiple major outlets have reported that President Donald Trump is considering an executive action that would push federal cannabis policy toward moving marijuana from Schedule I to Schedule III—potentially on a very fast timeline. The Washington Post+2Reuters+2

If you operate in regulated cannabis (cultivation, manufacturing, distribution, retail, labs, logistics, property, or professional services), the headline is simple:

Schedule III is not federal legalization—but it could be the most meaningful federal change for operators’ financials in decades, primarily through taxes. Congress.gov+2Moritz College of Law+2

Below is what’s being reported, what an executive order can (and can’t) do, and what we recommend businesses watch for and prepare.

What’s being reported right now

Recent reporting indicates President Trump may be preparing an executive order that directs his administration to finalize the long-running federal rescheduling effort—moving cannabis from Schedule I to Schedule III. The Washington Post+2Reuters+2

At the same time, officials have indicated no final decision has been made, and markets have swung sharply on rumor vs. confirmation. Barron’s+2Reuters+2

Why this matters: The U.S. has already been in an administrative rescheduling process for over a year. HHS recommended Schedule III, and DEA issued a proposed rule in 2024—followed by hearing activity and delays. Moritz College of Law+1

Can a President “reschedule” cannabis with an Executive Order?

Not directly.

Under the Controlled Substances Act, scheduling changes are typically done through an administrative rulemaking process led by DEA, with input from HHS/FDA and subject to procedural requirements and potential litigation. Moritz College of Law+1

What a president can do is use executive authority to direct priorities and timelines across the executive branch—especially the Department of Justice and DEA—potentially accelerating the path to a final rule (and/or changing how aggressively the government defends or advances that final rule). The Washington Post+1

In other words, an EO may be the “push,” but the legal endpoint is still typically a DEA final rule.

What Schedule III would actually change for cannabis businesses

1) The 280E tax impact (the biggest immediate operator issue)

Today, Internal Revenue Code 280E disallows normal business deductions for businesses trafficking Schedule I/II substances. Moving cannabis to Schedule III would generally remove cannabis from 280E’s scope—potentially improving cashflow and effective tax rates for many state-legal operators. Barron’s+2Congress.gov+2

2) Research and medical development

Schedule I status creates significant research friction; Schedule III would typically reduce barriers, making it easier to conduct larger-scale research and potentially accelerate medical-product pathways. Moritz College of Law+1

3) Compliance complexity does not disappear

Schedule III is still controlled under federal law. Depending on how DEA and other agencies implement and enforce a new posture, operators could face new compliance expectations and legal gray zones—especially where state-legal markets don’t map cleanly onto federal controlled-substance frameworks. (This is one reason the rescheduling debate draws both support and criticism.) Congress.gov+1

What Schedule III would not do

Even if cannabis becomes Schedule III, it does not automatically create:

• Federal legalization of adult-use cannabis MJBizDaily+1

• Interstate commerce for state-legal products MJBizDaily

• Instant banking reform or guaranteed access to major institutional finance (that still largely needs legislation and/or clearer guidance) MJBizDaily+1

• A single unified national regulatory framework (FDA/DEA authority and state programs can still clash) Congress.gov

What we’d watch for over the next few days

If you’re tracking this closely, here are the practical “signal vs. noise” markers:

1. A published executive order (or official White House statement) that explicitly directs DOJ/DEA action or timeline The Washington Post+1

2. DOJ/DEA issuance of a final rule (or formal procedural step that clearly tees up finalization) Moritz College of Law+1

3. Litigation posture: expect challenges regardless of outcome; the key will be whether courts pause implementation Congress.gov+1

Operational guidance for state-legal businesses if Schedule III advances

This is not legal advice, but it’s what we’d be preparing for from a business-risk standpoint:

• Model your 280E sensitivity: quantify the difference between current effective tax vs. a post-280E scenario; identify how you’d deploy freed-up cashflow (debt, capex, compliance, payroll, expansion). Barron’s+1

• Tighten cost accounting now: if your books are messy, you’ll have a harder time proving benefits and making fast decisions.

• Prepare investor/lender communications: markets may whipsaw; you want a clear, factual internal memo ready. Barron’s+1

• Don’t assume “anything goes”: state compliance (DCC, track-and-trace, lab testing, packaging, transport) remains the day-to-day reality—and federal risk doesn’t vanish overnight. Congress.gov+1

Bottom line

If President Trump does move to accelerate rescheduling, Schedule III would be a major shift—but it’s a narrow one: it mostly changes the federal classification and (potentially) taxes and research constraints; it does not instantly harmonize federal and state cannabis law. Barron’s+2Congress.gov+2

At Drivon Consulting, our recommendation is to treat this as a high-impact, high-uncertainty event: prepare the financial and compliance playbooks now, and wait for formal documentation (EO text + DEA action) before making irreversible business moves. Barron’s+1